Serum hyaluronan (hyaluronic acid) in breast cancer patients
โ Scribed by Bertrand Delpech; Bernard Chevallier; Nadine Reinhardt; Jean-Pierre Julien; Christian Duval; Catherine Maingonnat; Philippe Bastit; Bernard Asselain
- Publisher
- John Wiley and Sons
- Year
- 1990
- Tongue
- French
- Weight
- 283 KB
- Volume
- 46
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
โฆ Synopsis
Eighty-three women with breast cancer (57 with systemic metastasis, 26 without) were investigated for serum hyaluronan (HA) and compared to 50 patients with benign diseases of the breast. Hyaluronan was significantly increased in sera of metastatic patients compared to sera of non-metastatic patients (p < 0.OOOl) and also in sera of non-metastatic patients when compared to control sera (p < 0.01). The difference was not related to the number of metastatic sites involved. Three months after starting cytotoxic chemotherapy in metastatic patients, lower H A concentrations were observed in patients responding to chemotherapy. The initial level of serum HA had no predictive value concerning response to chemotherapy*
๐ SIMILAR VOLUMES
Serum phosphodiesterase I (PDE I) activity was determined in 13 control and 51 breast-cancer patients with various stages of disease. Patients with both localized and metastatic breast cancer had significantly elevated serum PDE I activity. The highest activity was seen in patients with liver metast
Eighty-one women admitted for breast tumor biopsy have been followed sequentially for 12 months. Thirty-one women had clinical stage I and II breast cancer and 50 had benign breast disease. All these women had serum immunoglobulin IgA, IgG, IgM and IgE levels measured by immunodiffusion and radioimm
The concentration of hyaluronan was measured in the serum from patients with tumors. The patients were divided into nine groups: two control groups, i.e., those with benign tumors and those having undergone radical surgery; and seven groups of patients with untreated malignant conditions, i.e, mesot